On Nov. 2, AMCP joined a pharmacy stakeholder coalition letter to CMS requesting the agency use its PREP Act authority to establish payment mechanisms for Medicare and Medicaid to reimburse pharmacists for COVID-19 patient assessment services.
On Oct. 28, AMCP joined a pharmacy stakeholder coalition letter to HHS requesting authorizations for pharmacists, pharmacy technicians and interns to order and administer antiviral medications and flu tests.
Immunoglobulin (IG) derived from the plasma of donors is used in the treatment of an array of disorders, including primary and secondary immune deficiency states and a variety of autoimmune and inflammatory disorders. To understand the appropriate and cost effective use of immunoglobulin, AMCP convened an expert panel of managed care stakeholders.
In October, AMCP joined other pharmacy organizations in supporting the Pharmacist's Fundamental Responsibilities and Rights released by APhA and the National Alliance of State Pharmacy Associations (NASPA). These principles focus on pharmacists' responsibilities and the workplace conditions necessary to fulfill those responsibilities.
AMCP submitted comments on the proposed FDA Prescription Drug User Fee Act Reauthorization commitment letter, supporting the agency's plans to increase resources for approval of cell and gene therapies and continued exploration of uses for real-world evidence in regulatory decision-making.